Literature DB >> 12871027

Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets.

E Guastamacchia1, F Resta, A Mangia, F Schittulli, A Ciampolillo, V Triggiani, B Licchelli, A Paradiso, C Sabbà, E Tafaro.   

Abstract

HYPOTHESIS: Epidemiological data have suggested a possible relationship between diabetes mellitus and cancer risk, particularly breast cancer. We set out to investigate the effect of diabetes mellitus on the expression of estrogen and progesteron receptors and on the proliferative activity of primary breast cancer.
METHODS: We selected 77 diabetic women and 578 control patients all in post-menopause and diagnosed with primary breast cancer. All patients underwent surgical excision of the tumor and on the specimens were performed an assessment of estrogen receptor and progesteron receptor and proliferative activity assay by (3)H-Thymidine incorporation.
RESULTS: Diabetic women showed a decreased proliferative activity, while having the same estrogen receptor and progesteron receptor status and mean cytoplasmic concentration of their receptors than control group. Insulin treated women had a lower proliferative activity than non-insulin treated ones.
CONCLUSION: Hyperinsulinemia and hyperglicemia influence in negative way the proliferative activity of diabetic women, likely inducing the expression of transforming growth factor beta, despite the high serum levels of Insulin-like growth factor and estrogen.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871027     DOI: 10.2174/1568008033340199

Source DB:  PubMed          Journal:  Curr Drug Targets Immune Endocr Metabol Disord        ISSN: 1568-0088


  8 in total

1.  Clinicopathological characteristics and prognosis of breast cancer patients with type 2 diabetes mellitus.

Authors:  D E He; Jing-Wen Bai; Jing Liu; Cai-Wen DU; Wen-He Huang; Guo-Jun Zhang
Journal:  Mol Clin Oncol       Date:  2015-03-02

2.  More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin.

Authors:  Lev M Berstein; Marina P Boyarkina; Evgenia V Tsyrlina; Elena A Turkevich; Vladimir F Semiglazov
Journal:  Med Oncol       Date:  2010-05-20       Impact factor: 3.064

3.  Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer.

Authors:  Tomasz P Srokowski; Shenying Fang; Gabriel N Hortobagyi; Sharon H Giordano
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

4.  Histological evaluation of AMPK signalling in primary breast cancer.

Authors:  Sirwan M Hadad; Lee Baker; Philip R Quinlan; Katherine E Robertson; Susan E Bray; George Thomson; David Kellock; Lee B Jordan; Colin A Purdie; David G Hardie; Stewart Fleming; Alastair M Thompson
Journal:  BMC Cancer       Date:  2009-09-01       Impact factor: 4.430

5.  Type 2 diabetes mellitus, oral diabetic medications, insulin therapy, and overall breast cancer risk.

Authors:  Hala Ahmadieh; Sami T Azar
Journal:  ISRN Endocrinol       Date:  2013-01-17

6.  Metabolic profile of breast cancer in a population of women in southern Spain.

Authors:  Juan-Bosco Lopez-Saez; Jose Antonio Martinez-Rubio; Maria Montes Alvarez; Carmen Gonzalez Carrera; Margarita Dominguez Villar; Antonio Garcia de Lomas Mier; Charo Doménech; Avelino Senra-Varela
Journal:  Open Clin Cancer J       Date:  2008-01-18

7.  Insulin glargine versus other types of basal insulin-clinical and tumor characteristics in patients with breast carcinoma.

Authors:  Nikola Besic; Nika Satej
Journal:  BMC Res Notes       Date:  2013-10-16

8.  Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients - a retrospective study of clinical and tumor characteristics.

Authors:  Nikola Besic; Nika Satej; Ivica Ratosa; Andreja Gojkovic Horvat; Tanja Marinko; Barbara Gazic; Rok Petric
Journal:  BMC Cancer       Date:  2014-04-28       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.